MarketInsite Stocks Graphic

Nasdaq’s Jordan Saxe Speaks to Forbes on the BioTech Industry

Nasdaq's Jordan Saxe Speaks to Forbes on the Biotech Industry

In the first half of 2018, Nasdaq led in U.S. listings with a healthcare initial public offering (IPO) win rate of 95%. Jordan Saxe, our Senior Managing Director and Head of Healthcare Capital Markets, spoke to Forbes contributor Arlene Weintraub to provide his analysis of the current healthcare markets.

“This is more activity than we thought we would initially see,” says Saxe. He adds that many biotech companies have expressed interest in planning their IPOs for fall and early 2019.

Read about the trends Jordan Saxe thinks are are fueling the IPO frenzy in the full Forbes article here.

Jordan B. Saxe is Senior Managing Director, Listing Services at Nasdaq. He is responsible for leading business development efforts in the healthcare sector, and brings over thirteen years of experience within the exchange field. He has advised over 200 IPOs and has worked closely with venture capital, private equity and investment firms to educate them on the liquidity options Nasdaq can provide. He holds a B.S. in Business Administration from the University of Vermont.

Related Links:

Nasdaq's Head of Healthcare Shares Biotech IPO Predictions

Advisory Live: What is the outlook for healthcare IPOs?

Nasdaq Extends IPO Leadership and Welcome 151 New Listings in First Half of 2018

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest BioTech Videos

How The Nasdaq Biotech Index Is Performing Relative To The Market

Jun 21, 2022